- Home
- MVBF vs AVIR Comparison
MVBF vs AVIR Comparison
Compare MVBF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVBF | AVIR |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.9M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MVBF | AVIR |
|---|---|---|
| Price | $28.52 | $3.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $27.60 | $6.00 |
| AVG Volume (30 Days) | 79.3K | ★ 350.0K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 73.99 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $167,853,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.06 | N/A |
| P/E Ratio | $11.61 | ★ N/A |
| Revenue Growth | ★ 18.75 | N/A |
| 52 Week Low | $15.59 | $2.46 |
| 52 Week High | $28.72 | $4.02 |
Technical Indicators
Market Signals| Indicator | MVBF | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 50.30 |
| Support Level | $26.52 | $3.11 |
| Resistance Level | $28.72 | $3.27 |
| Average True Range (ATR) | 0.75 | 0.10 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 82.69 | 56.33 |
Price Performance
Historical ComparisonAbout MVBF MVB Financial Corp.
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).